FibroBiologics (Nasdaq: FBLG) Email Format
Biotechnology ResearchTexas, United States11-50 Employees
The company's work centers on cell therapy and tissue regeneration, aiming to translate fibroblast biology into treatments that address unmet medical needs. In May 2026, it announced the launch of CYWC628, a drug product intended for a Phase 1/2 trial in diabetic foot ulcers.